Moderna expands the field of mrna medicine with positive clinical results across cancer, rare disease, and infectious disease

Company's flu vaccine, mrna-1010, met its primary endpoint in phase 3 trial; separate phase 1/2 data demonstrated higher hai titers than fluzone hd vaccine pipeline advancing rapidly with company announcing the completion of rsv bla filing (mrna-1345), completion of adult enrollment in the phase 3 trial of mrna-1647, a first-in-class vaccine against cmv, and the phase 3 trial of mrna-1283, a next-generation covid-19 vaccine with its partner merck, the company plans to begin a second phase 3 trial of mrna-4157, its individualized neoantigen therapy (int), in combination with keytruda®, for non-small cell lung cancer later this year; updated efficacy follow-up from the ongoing phase 2 study in adjuvant melanoma expected in q4 with positive clinical data announced in mrna-3705, a treatment for methylmalonic acidemia, the company has three chronic rare disease medicines that have demonstrated potential for clinical benefit in patients over the next five years, the company expects to launch up to 15 new products addressing high unmet needs, to bring up to 50 new candidates into clinical trials and to continue expanding the field of mrna into new applications cambridge, ma / accesswire / september 13, 2023 / moderna, inc. (nasdaq:mrna) today announced business and clinical updates across its franchises and introduced several new development programs at the company's annual r&d day. "our mrna platform is working.
MRNA Ratings Summary
MRNA Quant Ranking